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Radiocontrast agents are thought to induce acute kidney
injury in part through increased production of reactive
oxygen species and increased cellular apoptosis. In this study
we determined whether heme oxygenase-1 could prevent or
reduce radiocontrast-induced acute kidney injury and, if so,
what were the mechanisms by which this can occur. Sodium
iothalamate was administered to uninephrectomized, salt-
depleted male Sabra rats to initiate acute kidney injury. Heme
oxygenase-1 was induced with cobalt protoporphyrin or
inhibited with stannous mesoporphyrin. Inhibition of heme
oxygenase exacerbated kidney injury as measured by an
increase in plasma creatinine and in superoxide production.
Heme oxygenase-1 induction prevented the increase in
plasma creatinine and in superoxide in both the cortex and
medulla compared to untreated rats with acute kidney injury.
This protective effect of heme oxygenase-1 was associated
with increased anti-apoptotic proteins Bcl-2 and Bcl-xl and a
decrease of pro-apoptotic caspase-3 and caspase-9 along
with increased expression of inactive BAX. Our study
suggests that increased levels of heme oxygenase-1 are
protective against acute kidney injury due to radiocontrast
exposure.
Kidney International (2007) 72, 945–953; doi:10.1038/sj.ki.5002447;
published online 1 August 2007
KEYWORDS: acute kidney injury; apoptosis; heme oxygenase; carbon
monoxide; caspase; oxidative injury
Heme oxygenase (HO), as the key enzyme in heme degrada-
tion, not only controls the cellular levels of heme available for
the synthesis of heme proteins but is also responsible for the
generation of bilirubin, an antioxidant, and the active gas,
carbon monoxide (CO).1–3 Two HO isoforms (HO-1 and
HO-2), the products of two distinct genes, have been
shown to be important in the catabolism of heme in
mammals. HO-2, which is constitutively expressed, is
localized primarily in the brain, testis, and the vascular
endothelium.1 HO-1, the inducible form, has been shown to
protect the kidney in several models of acute kidney injury
(AKI), such as ischemia- and glycerol-induced AKI,
nephrotoxic serum nephritis, cisplatin nephrotoxicity, and
rapamycin-induced AKI.4–8 In the glycerol model of AKI,
an increased release of heme was shown to cause renal
toxicity, whereas induction of HO-1 preserved renal function
and reduced inflammatory molecules.9
The beneficial effects of HO-1 induction in AKI are
thought to occur via several mechanisms. Increased HO-1
activity results in degradation of the heme moiety, which
is a pro-oxidant and potentially toxic to several cellular
targets, including lipid bilayers, mitochondria, cytoskeleton,
and components of the nucleus.10–12 In addition to
detoxifying heme, elevated HO-1 activity results in the
increased generation of bilirubin, an antioxidant capable of
scavenging peroxy radicals and inhibiting lipid peroxidation.2
Finally, HO-1 generates CO gas as a byproduct of the
breakdown of heme. Several studies have demonstrated
the protective role of CO itself in limiting renal damage in
ischemia-induced AKI.13–15
A potential mechanism of AKI is thought to be mediated
by the increased production of reactive oxygen species and
increased tubular cell apoptosis.16,17 Recent studies by Yano
et al.18 have reported that the radiocontrast agent, ioversol,
inhibits the cyclic adenosine mono phosphate-stimulated
phosphorylation of Akt, a kinase that when activated can
enhance Bcl-2 expression, and that stimulation of the cyclic
adenosine mono phosphate pathway to increase Akt
phosphorylation can prevent ioversol-induced apoptosis in
cultured renal tubular cells. Akt is known to be activated in
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response to increased HO-1 or CO generation and may play
an important role in preventing apoptosis.19–22 The effects
of HO-1 gene expression and activity on the Bcl-2 family
of pro- and anti-apoptotic proteins, which may be involved
in the restoration of renal function in AKI, remain to be
determined.
The goals of this study were to determine whether HO-1
induction is protective of renal function in radiocontrast-
induced AKI and if HO-1 induction inhibits superoxide (O2
)
production and the apoptotic signaling pathways activated
by AKI. Our results indicate a key role for HO-1 induction
in the prevention of radiocontrast-induced AKI through
mechanisms that involve inhibition of reactive oxygen species
generation as well as suppression of pro-apoptotic and
stimulation of anti-apoptotic proteins.
RESULTS
Effect of AKI on HO-1 and HO-2
The induction of AKI led to an increase in HO-1 protein in
the cortex, but not in the medulla, while no significant
differences in HO-2 protein expression were observed
(Figure 1a). Treatment with cobalt protoporphyrin (CoPP)
significantly increased HO-1 protein levels in the cortex and
in the medulla, but had no effect on the levels of HO-2
protein (Figure 1b). Stannous mesoporphyrin (SnMP) also
increased the levels of HO-1 protein.
Renal HO activity and heme measurements
To further define the effect of radiocontrast-induced AKI on
renal HO-1, we measured HO activity in control and AKI
rats before and after administration of CoPP or SnMP. HO
activity was 0.7170.032 nmol bilirubin/mg/h in controls
compared to 0.83570.057 nmol bilirubin/mg/h in AKI
rats (Figure 2a). Treatment with CoPP increased HO activity
to 2.1270.12 nmol bilirubin/mg/h, which was a 2.5-fold
increase in HO activity compared to nontreated AKI controls
(Po0.05). Weekly administration of SnMP decreased HO
activity by 50% (to 0.3470.026 nmol bilirubin/mg/h) despite
the fact that it increased HO-1 protein levels (Figure 2a).
As seen in Figure 2b, renal heme content was significantly
increased by kidney injury (0.6170.058 in control rats vs
0.9570.021 nmol/mg protein in AKI rats). Treatment with
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Figure 1 | Effect of AKI and CoPP on HO-1 and HO-2 expression. (a) Western blot and densitometry analysis of HO-1, HO-2, and actin in
the renal medulla and renal cortex from control and AKI rats. Results are expressed as mean7s.e., n¼ 4, *Po0.05 vs control. (b) Western
blot of HO-1, HO-2, and actin in the renal medulla and renal cortex from control, AKI, AKIþCoPP-, and AKIþ SnMP-treated rats (representative
of three experiments). 254 190 mm (300 300 d.p.i.).
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CoPP lowered renal heme content to 0.2870.048 nmol/mg
protein, while inhibition of HO with SnMP further
exacerbated the increase in renal heme content (averaging
1.14170104 nmol/mg protein) compared to nontreated
AKI rats.
Renal levels of eNOS and iNOS protein
AKI led to a dramatic reduction of endothelial nitric oxide
synthase (eNOS) protein while, at the same time, increasing
the levels of inducible nitric oxide synthase (iNOS) protein in
the kidney (Figure 3). Treatment with CoPP restored the
levels of eNOS protein to those observed in control rats and
was also able to attenuate the increase in iNOS protein levels
observed in AKI rats (Figure 3). SnMP treatment increased
the levels of iNOS protein in response to AKI, but had no
effect on eNOS levels.
Effect of HO-1 expression on O2
 anion
Compared to control rats, kidney injury significantly
increased O2
 production by about 1.8-fold from 5.8570.5
to 10.5370.6 mmol O2
/mg protein (Figure 4). Induction of
HO-1 with CoPP completely prevented the increase of O2

production by AKI, averaging 4.7270.4 mmol O2
/mg protein
(Po0.05). In contrast, inhibition of HO-1 with SnMP
significantly increased O2
 production to 12.4870.7 mmol
O2
/mg protein (Figure 4).
Effect of HO-1 expression on renal function
As seen in Figure 5a, the induction of AKI resulted in
an increase in plasma creatinine to 0.5570.08 mg%
compared to 0.4270.01 mg% in controls (Po0.05). CoPP
treatment prevented the increase in plasma creatinine
(0.3270.06 mg%; Po0.05), while rats treated with SnMP
plasma creatinine was similar to untreated AKI, 0.597
0.09 mg%. Glomerular filtration rate, as measured by the
clearance of creatinine, was significantly reduced in AKI
rats compared to controls, 1.8470.26 vs 3.9870.87 ml/min,
Po0.05 (Figure 5b). Creatinine clearance was significantly
higher after the induction of HO-1 with CoPP, averaging
2.8670.77 ml/min, while treatment with SnMP had no affect
on creatinine clearance, averaging 2.1170.37 ml/min.
Effect of HO-1 induction on pro- and anti-apoptotic
protein levels
AKI resulted in a significant increase in caspase-3 and
caspase-9 activities in the medulla (Figure 6). Since HO-1
has been shown to modulate the apoptotic pathway,23 we
examined the CoPP- and SnMP-mediated modulation of HO
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Figure 2 | Effect of AKI and CoPP on HO activity and heme
content. (a) HO activity in the renal cortex of control, AKI-,
AKIþCoPP-, and AKIþ SnMP-treated rats. (b) Heme content in the
renal cortex of control, AKI-, AKIþCoPP-, and AKIþ SnMP-treated
rats. Results are expressed as mean7s.e., n¼ 6, *Po0.05 vs control,
#Po0.05 vs AKI, wPo0.05 vs AKIþCoPP. 254 190 mm
(300 300 d.p.i.).
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Figure 3 | Western blot of eNOS and iNOS in the kidney of
control, AKI-, AKIþCoPP-, and AKIþ SnMP-treated rats
(representative of three experiments). 254 190 mm
(300 300 d.p.i.).
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Figure 4 | Superoxide anion (O2
) production in the renal cortex of
control, AKI-, AKIþCoPP-, and AKIþ SnMP-treated rats. Results
are expressed as mean7s.e., n¼ 6, *Po0.05 vs control, wPo0.05 vs
AKI and AKIþCoPP. 254 190 mm (300 300 d.p.i.).
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activity. As seen in Figure 6, the induction of HO-1 by CoPP
strongly abrogated the increase in caspase-3 and caspase-9
activity in the medulla, while there was no significant
difference in the cortex. SnMP, an inducer of HO-1 protein
but inhibitor of CO and bilirubin, did not decrease
caspase levels. These results suggest that it is not HO-1
protein, but HO-1-derived CO and bilirubin that regulate
caspase activity.
To investigate the possibility that the differential activation
of pro-apoptotic and anti-apoptotic proteins may account for
the effect seen in HO-1-modulated renal protection,
we examined the levels of Bax, Bcl-2, and Bcl-xl proteins in
the renal medulla and cortex. The induction of AKI
resulted in a significant increase in Bax levels in the medulla.
The levels of Bax in the cortex tended to be higher following
AKI, but the difference did not reach statistical significance
(Figures 7 and 8). The AKI-induced increase in Bax in the
medulla was prevented by CoPP treatment (Figures 7 and 8).
Notably, treatment with SnMP caused a dramatic augmen-
tation of the AKI-induced increase in Bax levels in
both the medulla and cortex (Figures 7 and 8). Treatment
with CoPP dramatically increased Bcl-2 expression in the
medulla. In the cortex, Bcl-2 expression levels tended to be
elevated by CoPP; however, the increase did not reach statistical
significance. Importantly, SnMP reduced cortical Bcl-2 levels in
AKI rats, even to below those of controls (Po0.05; Figure 8a
and b). Compared to controls and nontreated AKI rats,
CoPP-treated AKI animals had significantly increased Bcl-xl
levels in the medulla (Figure 7) and cortex (Figure 8).
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Figure 5 | Effect of AKI and HO-1 induction on
plasma creatinine and creatinine clearance. (a) Plasma
creatinine in control, AKI-, AKIþCoPP- and AKIþ SnMP-treated
rats. (b) Creatinine clearance in control, AKI-, AKIþCoPP-, and
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Figure 6 | Caspase-3 and caspase-9 activity in the renal medulla and cortex. Results are expressed as mean7s.e. (n¼ 4 in each group),
*Po0.05 vs control, #Po0.05 vs AKI. 254 190 mm (300 300 d.p.i.).
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DISCUSSION
This study demonstrates that HO-1 plays an important role
in renal protection in a radiocontrast model of AKI. Normal
renal function was maintained in AKI rats treated with CoPP.
CoPP treatment decreased heme levels and O2
 formation in
the kidney, presumably due to the induction of HO-1 and the
subsequent increased generation of bilirubin and CO. We
have also demonstrated a link between increased levels of
anti-apoptotic proteins and the HO-1-mediated prevention
of renal dysfunction and inhibition of tubular necrosis as
seen by the decrease in caspase activity. CoPP treatment
resulted in a robust increase in the anti-apoptotic proteins
Bcl-xl and Bcl-2, a decrease in the pro-apoptotic Bax protein,
and inhibition of caspase activity. Lastly, the induction of
HO-1 by CoPP decreased iNOS levels and increased the
levels of eNOS in the kidney in this model of radiocontrast-
induced AKI.
Our results clearly demonstrate that induction of HO-1 by
CoPP can protect the kidney from radiocontrast-induced
AKI. These results are consistent with previous observations
that HO-1 expression in renal tissue is cytoprotective in both
heme- and non-heme-mediated models of AKI. For example,
in a heme-mediated model of AKI associated with rhabdo-
myolysis, the administration of tin protoporphyrin (SnPP),
which is a specific inhibitor of HO, worsened renal damage,
while the induction of HO-1 led to a considerable decrease in
mortality.24 In in vitro studies with purified HO-1 and HO-2,
inhibitors of HO activity such as Sn- and Zn-protoporphyr-
ins were equally inhibitory to HO activity; athought, SnMP
was more inhibitory to HO-2-dependent activity than to
that of HO-1.25 In cisplatin-induced nephrotoxicity, inhibi-
tion of HO by SnMP significantly worsened both the
structural and functional parameters of renal injury,5
providing direct evidence for the role of HO (most likely
HO-1) in protecting the kidney in this model of AKI. Several
additional studies have also confirmed the protective role of
HO-1 induction in protecting the kidney and have described
the effect of HO inhibition as worsening kidney damage
following ischemia- and rapamycin-induced AKI.4,26,27
Our results demonstrate that induction of HO-1 was
associated with maintenance of glomerular filtration rate, as
indicated by normal creatinine clearances and plasma
creatinine levels in CoPP-treated AKI rats. Previous studies
have demonstrated a sharp decline in renal medullary blood
flow following administration of radiocontrast agents.28,29
CO generated from HO is a known vasodilator and has been
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Figure 7 | Effect of AKI and HO-1 expression on anti-apoptotic
signaling protein, Bcl-2 and Bcl-xl in the medulla. Western blot
(a) and densitometry analysis (b) of pro- and anti-apoptotic
proteins in the renal medulla of control, AKI, AKIþCoPP and
AKIþ SnMP rats. Results are expressed as mean7s.e. (n¼ 4 in
each group), *Po0.05 vs control, #Po0.05 vs AKI, wPo0.05 vs
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Figure 8 | Effect of AKI and HO-1 expression on anti-apoptotic
signaling protein, Bcl-2 and Bcl-xl in the cortex. Western blot (a)
and densitometry analysis (b) of pro- and anti-apoptotic proteins in
the renal cortex of control, AKI, AKIþCoPP and AKIþ SnMP rats.
Results are expressed as mean7s.e. (n¼ 4 in each group); *Po0.05 vs
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linked to the regulation of medullary blood flow in the
kidney.30 It is possible that the induction of HO-1 via CoPP
maintains adequate medullary blood flow, thus preventing
ischemic injury. In the current study, AKI was also associated
with a significant decrease in the level of eNOS protein in
the kidney. This decrease was completely prevented by
CoPP treatment. It is possible that the decrease in eNOS
contributes to the decreased glomerular filtration rate and
reduced regional blood flow in the kidney following
AKI. Restoration of eNOS by CoPP may be a contributing
factor to the improvement of blood flow and the prevention
of renal damage in AKI rats. CoPP treatment has been shown
to improve vascular function and increase eNOS levels in
diabetic rats.31 Radiocontrast-induced AKI has also been
associated with increased production of reactive oxygen
species, which may contribute to the elevation in vascular
tone and increased apoptosis observed in this pathological
condition.17,32 In the present study, sodium iothalamate-
induced AKI led to an increase in O2
 production in the
kidney, which was completely prevented by induction of
HO-1 with CoPP. Conversely, inhibition of HO activity with
SnMP led to a significant increase in O2
 production.
HO induction by CoPP also increased the production of
another potent antioxidant, bilirubin. Bilirubin has been
shown to be protective against oxidative injury in neurons as
well as in ischemic–reperfusion injury of the liver.33,34
Bilirubin has also been shown to inhibit protein kinase C
and NAD(P)H oxidase activities.35–37 Recently, the upregula-
tion of HO-1 gene expression was shown to decrease the
availability of the heme-containing gp91 subunit necessary
for NADPH oxidase activity and O2
 generation and to
increase bilirubin formation.38 Furthermore, a decrease in
mitochondrial heme as a result of the increase in mitochon-
drial HO-1 may reduce fatty acid lipid peroxidant generation
and enhance mitochondrial membrane resistance to oxidative
stress and increases mitochondrial function.39 Along with
increased bilirubin, induction of HO-1 by CoPP also leads to
increased production of CO. Recent studies have demon-
strated that CO can directly reduce the activity of NADPH
oxidase and lower O2
 production in vascular smooth muscle
cells reviewed by Abraham and Kappas.2 CO and biliverdin
protect vascular function and endothelial cell sloughing in
rats with type I diabetes.40 It is also possible that induction of
HO-1 with CoPP can increase the levels of other antioxidant
proteins such as catalase or superoxide dismutase to lower
O2
 production in the kidney of radiocontrast-induced AKI
rats, as similar observations were recently made in the
kidney of angiotensin II hypertensive mice, diabetic rats, or
HO-2siRNA rats treated with CoPP.41–43
Compared to controls, heme levels were significantly
increased in the kidneys of AKI rats. CoPP administration
reduced the increase in heme to levels that were even below
those observed in control rats. Conversely, the inhibition of
HO activity with SnMP significantly increased heme levels
compared to nontreated AKI rats. Induction of HO-1 has
been previously shown to be protective to the kidney in
models of AKI in which heme levels were increased.6 Thus,
the decrease in free heme content following CoPP may be
another mechanism by which CoPP decreases oxidative stress
and protects against radiocontrast-induced AKI. The
physiology and pathology of HO-1/HO-2 in kidney disease
has recently been reviewed by Tracz et al.44
Radiocontrast-induced AKI was associated with a marked
increased in iNOS protein in the kidney. This was attenuated
by CoPP treatment, which is in agreement with previous
studies examining the effect of HO-1 induction on iNOS
levels in diabetes.31 Induction of iNOS is a classical marker of
macrophage infiltration and increased inflammation in the
kidney. Previous studies have reported that inhibition or
knockout of the iNOS gene prevents the development of
renal injury after ischemia/reperfusion injury.45,46 High levels
of iNOS can also increase the levels of nitrosative stress
through the generation of peroxynitrite. Peroxynitrite can
cause protein nitrotyrosine modification, which can weaken
cellular antioxidant defenses, furthering renal injury. Thus,
reduction of nitrosative damage in radiocontrast-induced
AKI via the lowering of iNOS levels may play a role in the
protection afforded by induction of HO-1 with CoPP.
Another key observation is that upregulation of HO-1 by
CoPP decreased activation of caspase and pro-apoptotic Bax
protein levels as well as increased the levels of Bcl-xl and
Bcl-2 proteins, which are important for cell survival. The
changes in caspase activity, Bax, Bcl-2, and Bcl-xl appear to
be dependent on the total HO activity (HO-2 and HO-1).
SnMP inhibits HO activity, which led to a marked increase in
BAX and inhibits BCL-XL. Since SnMP caused substantial
inhibition of Bax and caspase activity, this suggests that
HO-2 plays a major role in regulating pro-apoptosis
pathway since SnMP caused dramatic increases in Bax levels.
HO-2 deficiency has been shown to contribute to an increase
in O2
 anion and renal dysfunction in HO-2 knockout
mice.47 Silencing HO-2 has been shown to increase caspase
and decreases extracellular superoxide dismutase.41,42
Recently, Kim et al.8 have shown that induction of HO-1
protects the rat kidney from ureteral obstruction via an
antiapoptotic pathway. The anti-apoptotic Bcl-2 and Bcl-xl
proteins have been shown to regulate mitochondrial
cytochrome c release and caspase activation during oxidant
injury.48,49 Enhancement of these specific survival signals
may lead to the preservation of renal function during oxidant
injury, as was observed in this study of radiocontrast-induced
AKI. Previous studies have shown that the anti-apoptotic
effects of CO depend upon both the phosphatidylinositol
3-kinase/Akt and the p38 mitogen-activated protein
kinase signaling pathways, which are able to enhance signal
transducers and activators of transcription 3 activation and
attenuate caspase activity.19,50
The kidney medulla has been shown to be particularly
vulnerable to radiocontrast injury.28,51 Interestingly, our
model revealed a difference in AKI-elicited HO-1 induction
between the medulla and cortex. HO-1 was induced in the
cortical but not in the medullary regions of radiocontrast-
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treated kidneys. Importantly, the lack of HO-1 in the medulla
was associated with activation of caspases and increased Bax
levels; both effects were absent in the cortex. These results
suggest that cortical induction of HO-1 may represent a local,
endogenous, anti-apoptotic mechanism in radiocontrast-
induced AKI, but the medullary response requires a strong
inducer, such as CoPP, to raise medullary HO-1 to protective
levels. Considering that the S3 segment of the proximal
tubule and the thick ascending limb of the loop of Henle
(TALH) are located in the medulla, it is not surprising that
these segments are involved. Previous work of ours52 has
shown that TALH cell survival after experiencing oxidative
stress injury (via angiotensin II) may be facilitated by
selective upregulation of HO-1, thereby, blocking inflamma-
tion and apoptosis. Chung and Perrella53 emphasized in an
editorial comment on that work that the role of HO-1 in
renoprotection is very dependent on the location of the
specific tubular cells that are responsive to HO-1.
In summary, our findings indicate that HO-1 prevents
AKI-induced renal dysfunction by a mechanism involving a
decrease in cellular heme as well as increases in CO and
bilirubin. The increase in heme metabolism was associated
with an increase in eNOS, and a decrease in iNOS. Thus,
induction of HO-1 enables the kidney to mount an
important host-defense response to resist the AKI-mediated
increase in oxidative stress and the resultant renal dysfunc-
tion. The upregulation of HO-1 expression caused a decrease
in the pro-apoptotic caspases and Bax levels, and increases in
both Bcl-2 and Bcl-2 signaling proteins; which suggests that
induction of HO-1-derived CO or bilirubin activates the pro-
survival and inhibits the pro-apoptotic signaling pathways.
These results suggest that HO-1 may be potentially beneficial
strategy to prevent AKI in clinical circumstances such as the
use of dye contrast in selected patients who might have a
propensity toward sustaining such renal injury.
MATERIALS AND METHODS
Animals
Male Sabra rats (Wistar-derived colony), weighing 260–380 g, were
used in all experiments. They were divided into four groups, six rats
per group: (A) controls, (B) uninephrectomized, (C) uninephrecto-
mized and pretreated with CoPP 1 mg/100 g body wt, subcuta-
neously, once 4 days before terminating the experiments, and (D)
uninephrectomized and pretreated with SnMP, 5 mg/100 g body wt,
subcutaneously, daily for 4 days before terminating the experiments.
On day 0, under anesthesia with pentobarbital (50 mg/kg/body
wt, intraperitonealy), the femoral artery was cannulated using a
polyethylene catheter (PE 50; Clay-Adams, Parsippany, NJ, USA)
that exited through the skin in the back of the neck to allow
for blood sampling and injection of the contrast agent. Rats were
housed in Nalgene metabolic cages (Nalge Co., Rochester, NY, USA),
fed standard rat chow, and allowed free access to water except for the
day of radiocontrast administration.
Development of AKI
To increase the likelihood of AKI, rats were subjected to reduction of
renal mass by uninephrectomy 3 weeks before exposure to the
contrast agent. All rats were then salt depleted by feeding a low
sodium diet for 7 days before exposure to the contrast media while
receiving daily treatment of furosemide (2 mg/kg) for 7 days. Pro-
staglandin production was also inhibited 1 h before contrast
administration by a single intravenous injection of indomethacin
(10 mg/kg). Sodium iothalamate contrast media (60% Angio-
Conray, Mallinckrodt Inc., St Louis, MO, USA) was injected
through the arterial cannula over approximately 2 min at the dosage
of 8.0 ml/kg body wt. This dose of sodium iothalamate has
previously been demonstrated to cause AKI in rats.28
Measurement of renal function and tissue harvesting
Renal function parameters were measured following administra-
tion of the contrast agent before killing. Under light halothane
anesthesia, tail blood samples (0.5 ml) were collected into hepari-
nized tubes and plasma was obtained following centrifugation.
Urine was collected 24 h before sacrifice. Serum and urine creatinine
were determined using standard assays (Sigma Creatinine kit 555A,
Sigma, St Louis, MO, USA). Urine volume was also determined. At
the time of killing, animals were deeply anesthetized with ketamine/
xylazine/acepromazine (2.0/0.6/0.3 mg/kg). Kidneys were removed
and cut bilaterally; one-half was snap frozen in liquid nitrogen and
stored at 701C for subsequent biochemical analysis.
Cortex and outer medulla preparation
Kidneys were perfused with ice-cold hydroxyethylpiperazine-N0-2-
ethanesulfonic solution, sliced, and dissected to separate the cortex
and outer medulla as described previously.54 Tissue segments were
homogenized (4 ml/g wet weight) in 10 mM Tris buffer (pH 7.5)
containing 0.25 M sucrose. The homogenates were centrifuged
at 27 000 g for 20 min at 41C. The supernatant was centrifuged at
105 000 g for 1 h at 41C, and the resulting microsomal pellet was
resuspended in 0.1 M potassium phosphate buffer (pH 7.6).
Western blotting
For tissue homogenates, 30mg of protein was combined with sample
buffer and separated on an sodium dodecyl sulfate-polyacrylamide
gel. Gel percentages were 8% for proteins with molecular weights of
60 kDa and above, 12% for proteins with molecular weights of
25–60 kDa, and 15% for molecular weights less than 25 kDa. For
immunoblotting, the separated proteins were electrophoretically
transferred to PVDF membranes for 70 min at a constant 50 mA
per membrane. The membranes were then blocked with 10% milk in
10 mM Tris base, 150 mM NaCl, and 0.1% Tween at 41C overnight.
After being washed with Tris-buffered saline with Tween, the
membranes were incubated with 1:1000 dilutions in 3% milk in
Tris-buffered saline with Tween or commercial bovine serum albumin
as per manufacturer’s instructions for anti-HO-1 and anti-HO-2
(Stressgen Biotechnologies Corp., Victoria, BC, Canada), anti-eNOS
and anti-iNOS (Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA), anti-b actin (Sigma), anti-Bax, anti-Bcl-xl, and anti-Bcl-2 (Cell
Signaling Technology Inc., Danvers, MA, USA) for 2 h at room
temperature with constant shaking. The filters were rinsed twice,
washed three times with Tris-buffered saline with Tween for 10 min,
and then probed with horseradish peroxidase-conjugated anti-rabbit
secondary antibodies (anti-mouse for b-actin) at dilutions of 1:2000
for 1 h at room temperature with constant shaking. The filters were
again rinsed twice and washed three times with Tris-buffered saline
with Tween for 10 min. Chemiluminescence detection was performed
with the Amersham ECL Plus Detection kit (Amersham, Piscataway,
NJ, USA) according to the manufacturer’s instructions.
Kidney International (2007) 72, 945–953 951
AI Goodman et al.: HO-1 and acute renal injury o r i g i n a l a r t i c l e
Measurement of HO activity and heme content
Tissues were homogenized (4 ml/g wet weight) in homogenization
buffer (pH 7.4), containing 0.25 M sucrose. The homogenates were
centrifuged at 10 000 g for 10 min at 41C. The supernatant, contain-
ing cytosolic biliverdin reductase, was then used for measuring HO
activity. HO activity was assayed by a method in which bilirubin, the
end product of heme degradation, is extracted with chloroform and
its concentration is determined spectrophotometrically (Dual UV/
VIS Beam Spectrophotometer l 25; Perkin-Elmer, Norwalk, CT,
USA) using the difference in absorbance at wavelength from l 460 to
l 530 nm with an absorption coefficient of 40 mM1 and cm1.55
Heme content was determined by the pyridine hemochromogen
method as described previously.55 The absorbance difference between
l 557 and l 530 nm was used to calculate the heme content using an
extinction coefficient of 20.7 mM1 and cm1.
O2
 anion production
O2
 production was assayed by the spectrophotometric measure-
ment of Ferricytochrome c reduction. Kidney homogenates were
frozen (801C) until use. Tissue homogenates were incubated with
0.5 ml of reaction mixture, consisting of Krebs Ringer phosphate
buffer containing 80 mM cytochrome c and 2 mM NaN3. After 1 h of
incubation at 371C, the supernatants were collected and used to
assay the amount of reduced cytochrome c by the difference in
absorbance at 550–468 nm. O2
 release was calculated using a
coefficient of 0.0245 (the extinction coefficient mM/l of cytochrome c
determined at 550–468 nm), and expressed as mmol O2
/mg protein.
Caspase activity assay
Caspase-3 and caspase-9 activity was determined using colorimetric
assays (ApoTarget kit) following the manufacturer’s protocol
(BioSource International, Camarillo, CA, USA). Briefly, tissue cell
lysates were prepared in cell lysis buffer (Tris-buffered saline
containing detergent) and protein concentrations in samples were
estimated using the Bradford method. Then, 200–300 mg of protein
lysate per sample was mixed with 200 mM substrate in 2 reaction
buffer (DEVD-pNA for caspase-3 and LEHD-pNA for caspase-9)
and incubated at 371C overnight in the dark. Developed color was
measured at 405 nm in a microplate reader (Bio-Rad, Hercules, CA,
USA). Blank readings were subtracted from each sample before
calculation. Caspase activity was expressed in terms of absorbance
units (OD 405 nm) per milligram of protein.
Statistical analysis
The data are presented as mean7s.e. for the number of
experiments. Statistical significance (Po0.05) between the experi-
mental groups was determined by the Fisher methods for multiple
comparisons. For comparison between treatment groups, the null
hypothesis was tested by single factor analysis of variance for
multiple groups, or unpaired t-test for two groups.
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